XML 56 R46.htm IDEA: XBRL DOCUMENT v3.23.2

COMMITMENTS AND CONTINGENCIES - Additional Information (Detail) shares in Millions		1 Months Ended				3 Months Ended		6 Months Ended
	Dec. 30, 2021 USD ($) shares	May 31, 2023 USD ($)	Aug. 31, 2022 USD ($) product	Dec. 31, 2021 USD ($)	Dec. 31, 2016 USD ($) product	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($)
Loss Contingencies [Line Items]
Research and development						$ 5,998,766	$ 6,046,670	$ 12,613,482	$ 13,878,939
Research plan and budget, expected costs		$ 3,500,000	$ 3,000,000
License Agreement
Loss Contingencies [Line Items]
License agreement milestone payments (up to)			$ 452,000,000
Developmental milestone approvals, number of products (at least) | product			3
Advance written notice required to terminate agreement								90 days
Northwestern University | License Agreement
Loss Contingencies [Line Items]
Upfront non-creditable one-time license issuance fee payment					$ 75,000
Annual license maintenance fee payable					20,000
Consideration payable for rights grant					$ 5,300,000
Minimum number of product covered under license agreement | product					1
Northwestern University | License Agreement | Maximum
Loss Contingencies [Line Items]
Royalty obligation period					10 years
AstraZeneca
Loss Contingencies [Line Items]
Upfront cash payment	$ 5,000,000
License agreement, consideration (in shares) | shares	7.3
Days immediately preceding the execution date	30 days
Research and development				$ 12,300,000
License agreement milestone payments (up to)	$ 203,000,000
Lundbeck
Loss Contingencies [Line Items]
First payment due upon completion of first phase	$ 3,000,000

X

- Definition

Annual license maintenance fee payable.

+ References

No definition available.

+ Details

Name:	ovid_AnnualLicenseMaintenanceFeePayable
Namespace Prefix:	ovid_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Collaboration and Option Agreement, Research Plan And Budget, Expected Costs

+ References

No definition available.

+ Details

Name:	ovid_CollaborationAndOptionAgreementResearchPlanAndBudgetExpectedCosts
Namespace Prefix:	ovid_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Common Stock Issuance , Period Immediately Preceding Execution Date

+ References

No definition available.

+ Details

Name:	ovid_CommonStockIssuancePeriodImmediatelyPrecedingExecutionDate
Namespace Prefix:	ovid_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Consideration payable for rights grant.

+ References

No definition available.

+ Details

Name:	ovid_ConsiderationPayableForRightsGrant
Namespace Prefix:	ovid_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

First payment due upon completion of first phase.

+ References

No definition available.

+ Details

Name:	ovid_FirstPaymentDueUponCompletionOfFirstPhase
Namespace Prefix:	ovid_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

License Agreement, Consideration, Shares Issued

+ References

No definition available.

+ Details

Name:	ovid_LicenseAgreementConsiderationSharesIssued
Namespace Prefix:	ovid_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

X

- Definition

License Agreement, Development Milestone Approvals, Product Threshold

+ References

No definition available.

+ Details

Name:	ovid_LicenseAgreementDevelopmentMilestoneApprovalsProductThreshold
Namespace Prefix:	ovid_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

X

- Definition

Global commercial and regulatory milestone payments.

+ References

No definition available.

+ Details

Name:	ovid_LicenseAgreementMilestonePayments
Namespace Prefix:	ovid_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

License Agreement, Termination, Advance Notice Period

+ References

No definition available.

+ Details

Name:	ovid_LicenseAgreementTerminationAdvanceNoticePeriod
Namespace Prefix:	ovid_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Minimum number of product covered under license agreement

+ References

No definition available.

+ Details

Name:	ovid_MinimumNumberOfProductCoveredUnderLicenseAgreement
Namespace Prefix:	ovid_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Royalty Obligation, Term

+ References

No definition available.

+ Details

Name:	ovid_RoyaltyObligationTerm
Namespace Prefix:	ovid_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Upfront Cash Payment

+ References

No definition available.

+ Details

Name:	ovid_UpfrontCashPayment
Namespace Prefix:	ovid_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Upfront non-creditable one-time license issuance fee payment.

+ References

No definition available.

+ Details

Name:	ovid_UpfrontNonCreditableOneTimeLicenseIssuanceFeePayment
Namespace Prefix:	ovid_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 460
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482425/460-10-50-3

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483076/450-20-50-1

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483076/450-20-50-4

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483076/450-20-50-4

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483076/450-20-50-9

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483076/450-20-50-9

+ Details

Name:	us-gaap_LossContingenciesLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 730
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482916/730-10-50-1

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 912
-SubTopic 730
-Name Accounting Standards Codification
-Section 25
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482517/912-730-25-1

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481283/985-20-50-1

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=ovid_LicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=ovid_NorthwesternUniversityMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=ovid_AstrazenecaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=ovid_HLundbeckASMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: